GSK Plc ADR’s filing revealed that its 10% Owner GSK plc acquired Company’s shares for reported $22.34 million on Sep 27 ’24. In the deal valued at $8.00 per share,2,791,930 shares were bought. As a result of this transaction, GSK plc now holds 16,775,691 shares worth roughly $614.33 million.
Exane BNP Paribas initiated its GSK Plc ADR [GSK] rating to a Neutral in a research note published on April 15, 2025; the price target was $35.25. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who began to cover the stock in mid February with a ‘”an Equal-weight”‘ rating. Deutsche Bank also remained covering GSK and has decreased its forecast on November 15, 2024 with a “Hold” recommendation from previously “Buy” rating. Jefferies revised its rating on November 12, 2024. It rated GSK as “a Hold” which previously was an “a Buy”.
Price Performance Review of GSK
On Friday, GSK Plc ADR [NYSE:GSK] saw its stock fall -0.68% to $36.62. Over the last five days, the stock has lost -6.27%. GSK Plc ADR shares have risen nearly 8.28% since the year began. Nevertheless, the stocks have fallen -17.06% over the past one year. While a 52-week high of $45.92 was reached on 03/10/25, a 52-week low of $31.72 was recorded on 01/14/25. SMA at 50 days reached $37.83, while 200 days put it at $37.64.
Levels Of Support And Resistance For GSK Stock
The 24-hour chart illustrates a support level at 36.42, which if violated will result in even more drops to 36.23. On the upside, there is a resistance level at 36.98. A further resistance level may holdings at 37.34. The Relative Strength Index (RSI) on the 14-day chart is 44.57, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.99, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 87.34%. Stochastics %K at 25.18% indicates the stock is a holding.
